Home>Topics>Companies>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. DME patients fare better with Eylea compared to laser photocoag


    Fri, 18 Jul 2014

    the safety and efficacy of Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) to laser ..... those receiving injections of Eylea showed a sustained improvement ..... Study subjects receiving Eylea 2 mg every month had a mean

  2. Sanofi- Regeneron drug tames eczema in study


    Wed, 9 Jul 2014

    PARIS/NEW YORK, July 9 (Reuters) - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly

  3. Sanofi Is Buying Shares Of Regeneron - You Should Too


    Wed, 9 Jul 2014

    Jonathan Koss : Regeneron Pharmaceuticals , Inc . ( REGN ) is a U.S ..... FDA approved Regeneron 's Eylea , a treatment for ..... following two years, Regeneron 's share price ..... predicted success of Eylea and its high sales

  4. Sanofi raises stake in Regeneron to 22.5 percent from 20.5 percent


    Tue, 1 Jul 2014

    July 1 (Reuters) - French drugmaker Sanofi SA will raise its stake in Regeneron Pharmaceuticals Inc to 22.5 percent, Sanofi said in a U.S. regulatory filing Tuesday, as part of an agreement between...

  5. CHMP recommends label expansion for Eylea


    Fri, 27 Jun 2014

    Agency (EMA) approve Regeneron Pharmaceuticals ' ( REGN ) Eylea ( aflibercept ) injection ..... macular edema (DME). Eylea is currently approved ..... occlusion (CRVO). Regeneron and Bayer Healthcare ..... global development of Eylea . Regeneron has exclusive

  6. BRIEF-U.S. judge rejects Merus bid to dismiss Regeneron patent lawsuit


    Thu, 19 Jun 2014

    June 19 (Reuters) - Regeneron Pharmaceuticals Inc : * U.S. judge denies merus bv's bid to dismiss Regeneron Pharmaceuticals inc 's

  7. Positive Phase 3 results for sarilumab


    Thu, 12 Jun 2014

    interrupts the resultant cytokine-mediated inflammatory signalling. Sarilumab is being co-developed by Regeneron Pharmaceuticals ( REGN -0.2% ) and Sanofi ( SNY ). Post your comment!

  8. Eylea label expansion application submitted to EMA


    Wed, 11 Jun 2014

    Regeneron Pharmaceuticals ( REGN ) reports that collaboration ..... European Union for Eylea (aflibercept) for ..... has also approved Eylea for wet AMD and Macular ..... Diabetic Macular Edema. Regeneron has exclusive rights to Eylea in the U.S. Bayer

  9. New Morningstar Analyst Report for Roche Holding AG

    Stock Reports

    Tue, 3 Jun 2014

    several significant drugs in the interim. Blockbuster eye disease drug Lucentis is witnessing intense competition from Regeneron 's Eylea , and while we expect the drug to hold its own, we doubt Lucentis will continue to serve as the growth driver it has been

  10. Eylea's 1Q U.S. Sales Soft; Regeneron's Strong Pipeline Progress Continues; Maintaining FVE


    Thu, 8 May 2014

    Regeneron reported first-quarter results that ..... disappointing due to sluggish sales of Eylea in the U.S. However, the company ..... first quarter of 2013. Revenue included Eylea U.S. net product sales of $359 million ..... market share trends. Rest-of-world Eylea sales, as reported by partner Bayer

« Prev12345Next »
Content Partners